Beijing Chengyi Medical Technology

Chengyi Biopharma is a clinical-stage biopharmaceutical company headquartered in China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic and cardiovascular diseases. The company's primary focus is on high-prevalence conditions such as obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH). Their lead programs include oral GLP-1 receptor agonists and THR-beta selective agonists, designed to provide more convenient and effective treatment options compared to existing injectable therapies. Chengyi Biopharma leverages its internal R&D capabilities to advance a pipeline of highly selective compounds through clinical development and strategic global partnerships.